Edward Medeiros, DO
Nephrology · Warwick, RINPI 1144616715
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,700 of the $46,716 with a category attached, or 74.3%. AstraZeneca accounts for 85.0% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2024 at $25,185 and has fallen 74.7% since, to $6,363 in 2025. Among nephrology clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 427 payments — averaging $109.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$40K
- Otsuka America Pharmaceutical, Inc.$783
- Amgen$770
- Bayer$643
- Vifor Pharma, Inc.$616
- GSK$481
- plus $4K from 23 others
What the payments were for
- Consulting fees$1100%
- Speaking & faculty fees$34,70074%
- Travel & lodging$3281%
- Food & beverage$11,19024%
- Education$3881%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 130 | $39,731 |
| Otsuka America Pharmaceutical, Inc. | 32 | $783 |
| Amgen(2 entities) | 25 | $770 |
| Bayer | 25 | $643 |
| Vifor Pharma, Inc. | 31 | $616 |
| GSK | 28 | $481 |
| Calliditas Therapeutics US Inc. | 15 | $431 |
| OPKO Pharmaceuticals, LLC | 22 | $403 |
| Boehringer Ingelheim | 18 | $401 |
| Fresenius USA Marketing, Inc. | 19 | $351 |
| Aurinia Pharma U.S., Inc. | 12 | $311 |
| Akebia Therapeutics Inc | 10 | $224 |
| Travere Therapeutics, Inc. | 14 | $215 |
| Daiichi Sankyo Inc. | 2 | $165 |
| Azurity Pharmaceuticals, Inc. | 8 | $154 |
| Arbor Pharmaceuticals, Inc. | 6 | $133 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $132 |
| Novo Nordisk | 5 | $131 |
| Vantive US Healthcare LLC | 1 | $116 |
| Ardelyx, Inc. | 5 | $110 |
| Mallinckrodt Hospital Products Inc. | 4 | $97 |
| Nxstage Medical, Inc. | 1 | $80 |
| Ultragenyx Pharmaceutical Inc. | 3 | $66 |
| Alnylam Pharmaceuticals Inc. | 2 | $55 |
| Lexicon Pharmaceuticals, Inc. | 2 | $35 |
| Novartis | 1 | $29 |
| CMP Pharma, Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$29,489
- LOKELMA$7,827
- INJECTAFER$142
- Parsabiv$125
- TARPEYO$125
- Kerendia$124
- KRYSTEXXA$119
- Renal - PD$116
- BENLYSTA$110
- LUPKYNIS$105
How this compares
$46,716 in reported general payments places this provider in the 95th percentile of 45 nephrology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 71 | $158,124 |
| FarxigaDapagliflozin Propanediol | 150 | $122,332 |
| XphozahTenapanor Hcl | 19 | $76,658 |
| LokelmaSodium Zirconium Cyclosilicate | 57 | $59,607 |
| JardianceEmpagliflozin | 69 | $42,888 |
| VeltassaPatiromer Calcium Sorbitex | 52 | $33,693 |
| AuryxiaFerric Citrate | 17 | $20,306 |
| Lanthanum Carbonate | 32 | $14,954 |
| Sevelamer Carbonate | 83 | $10,928 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 37 | $9,794 |
| KerendiaFinerenone | 12 | $8,149 |
| Eplerenone | 35 | $6,683 |
| Cinacalcet Hcl | 16 | $3,504 |
| Losartan Potassium | 264 | $3,306 |
| Bumetanide | 67 | $3,106 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $39,731 | $181,939207 claims |
| Fresenius USA Marketing, Inc.Velphoro | $351 | $158,12471 claims |
| Boehringer IngelheimJardiance | $401 | $42,88869 claims |
| Akebia Therapeutics IncAuryxia | $224 | $20,30617 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $133 | $9,79437 claims |
| BayerKerendia | $643 | $8,14912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 45 nephrology providers in Rhode Island.
Other nephrology in Warwick
- Maroun AzarWarwick$473
- Nelson ChuWarwick$196
- Mary GaffneyWarwick$181
- Reginald GohhRiverside$47K
- Ankur ShahRiverside$27K
- Jie TangRiverside$23K
- Douglas SheminRiverside$22K
- Keith BartolomeiProvidence$15K
- Elkin EstradaProvidence$11K
- Katherine DavorenProvidence$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.